Atomoxetine, a Novel Treatment for Attention-Deficit-Hyperactivity Disorder

Alisa K. Christman, Pharm.D.; Joli D. Fermo, Pharm.D.; John S. Markowitz, Pharm.D.


Pharmacotherapy. 2004;24(8) 

In This Article


Atomoxetine is approved by the FDA for the treatment of ADHD in children, adolescents, and adults and has been proved effective for controlling symptoms that last throughout the day and into the evening. Data suggest that atomoxetine is effective in children and adolescents with ADHD of the mixed subtype, as well as with concomitant ODD. It is a reasonable alternative to stimulants in those who do not respond to treatment or in patients who are unable to tolerate stimulants. In addition, atomoxetine treatment has been proved effective in adults with a new diagnosis of ADHD or in those adults with ADHD who are unable to tolerate a stimulant. An added benefit of atomoxetine is its noncontrolled status, making it convenient for parents acquiring supplies of the drug for more than 1 month and favorable for patients with a high abuse potential. Additional advantages with atomoxetine are persistent symptom control into the evening, a decreased risk of user rebound, and a lower risk of induction of tics and psychosis.